Ovarian cancer in patients with BRCA1 5382insC mutation

Molecular genetic characteristics of the ovarian tumors can provide much quicker information about treatment effectiveness. The paper was aimed to study the frequency of BRCA1 5382insC mutation among ovarian cancer patients living in Siberia (the Tomsk region) and to detect the main clinical morphological and immunohistochemical characteristics of this disease. It was found that the frequency of BRCA1 5382insC mutation among ovarian cancer patients in the Tomsk region was 9.19 %. The partial response to platinum-based chemotherapy was observed in 75 % of ovarian cancer patients having BRCA1 5382insC mutation. Optimal cytoreduction is a significant predictor of the treatment effectiveness of hereditary ovarian cancer associated with BRCA1 5382insC mutation.